Diversity of the basic defect of homozygous CFTR mutation genotypes in humans by Stanke, F. et al.
Diversity of the basic defect of homozygous CFTR
mutation genotypes in humans
F Stanke,1,2 M Ballmann,2 I Bronsveld,4 T Do¨rk,3 S Gallati,5 U Laabs,1 N Derichs,2
M Ritzka,1,2 H-G Posselt,6 H K Harms,7 M Griese,7 H Blau,8 G Mastella,9 J Bijman,10
H Veeze,11 B Tu¨mmler1,2
1 Klinische Forschergruppe and
Abteilungen fu¨r; 2 Pa¨diatrische
Pneumologie und Neonatologie
and; 3 Gyna¨kologie und
Geburtshilfe, Medizinische
Hochschule Hannover,
Hannover, Germany;
4 Department of Pulmonology
and Tuberculosis, Universitair
Medisch Centrum Utrecht,
Utrecht, The Netherlands;
5 Abteilung fu¨r Humangenetik,
Medizinische
Universita¨tskinderklinik,
Inselspital, Universita¨t Bern,
Bern, Switzerland; 6 Universita¨ts-
Kinderklinik, Johann-Wolfgang-
Goethe Universita¨t, Frankfurt/
Main, Germany; 7 Dr von
Haunersches Kinderspital,
Ludwig-Maximilians-Universita¨t,
Munich, Germany; 8 Pulmonary
and Cystic Fibrosis Unit,
Schneider Children’s Medical
Center of Israel, Petah-Tikva,
and Sackler School of Medicine,
Tel-Aviv University, Tel-Aviv,
Israel; 9 Cystic Fibrosis Center,
Ospedale Civile Maggiore,
Piazzale Stefani, Verona, Italy;
10 Erasmus University
Rotterdam, Department of
Neurosciences, Rotterdam, The
Netherlands; 11 Stichting
Diabeter, Rotterdam, The
Netherlands
Correspondence to:
Dr Burkhard Tu¨mmler, Klinische
Forschergruppe, OE 6710,
Medizinische Hochschule
Hannover, Carl-Neuberg-Str. 1,
D-30625 Hannover, Germany;
tuemmler.burkhard@mh-
hannover.de
Received 31 July 2007
Revised 18 September 2007
Accepted 24 September 2007
This paper is freely available
online under the BMJ Journals
unlocked scheme, see http://
jmg.bmj.com/info/unlocked.dtl
ABSTRACT
Background: Knowledge of how CFTR mutations other
than F508del translate into the basic defect in cystic
fibrosis (CF) is scarce due to the low incidence of
homozygous index cases.
Methods: 17 individuals who are homozygous for
deletions, missense, stop or splice site mutations in the
CFTR gene were investigated for clinical symptoms of CF
and assessed in CFTR function by sweat test, nasal
potential difference and intestinal current measurement.
Results: CFTR activity in sweat gland, upper airways and
distal intestine was normal for homozygous carriers of
G314E or L997F and in the range of F508del homozygotes
for homozygous carriers of E92K, W1098L, R553X,
R1162X, CFTRdele2(ins186) or CFTRdele2,3(21 kb).
Homozygotes for M1101K, 1898+3 A-G or 3849+10 kb
C-T were not consistent CF or non-CF in the three
bioassays. 14 individuals exhibited some chloride con-
ductance in the airways and/or in the intestine which was
identified by the differential response to cAMP and DIDS
as being caused by CFTR or at least two other chloride
conductances.
Discussion: CFTR mutations may lead to unusual
electrophysiological or clinical manifestations. In vivo and
ex vivo functional assessment of CFTR function and in-
depth clinical examination of the index cases are indicated
to classify yet uncharacterised CFTR mutations as either
disease-causing lesions, risk factors, modifiers or neutral
variants.
Cystic fibrosis (CF) is an autosomal recessive
disorder of all exocrine glands and is caused by
mutations in the Cystic Fibrosis Transmembrane
Conductance Regulator (CFTR) gene.1 CFTR is
localised in the apical membrane of epithelial cells
and confers cAMP-activatable transport of chlor-
ide, bicarbonate and glutathione.1 The basic defect
in CF impairs the apical permeability for chloride
and is assessed in humans by the increased chloride
concentrations in sweat,2 the low chloride con-
ductance of upper airway epithelium3 or the lower
chloride secretory response of the intestinal epithe-
lium to secretagogues.4
The major mutation F508del is found on about
70% of CF alleles, but all other (.1300) known
disease-causing lesions are rare with a frequency
ranging from 2% to less than 0.01% in Caucasian
populations (http://www.genet.sickkids.on.ca/
cftr/).5 Hence the CFTR phenotype of most
mutations other than F508del has been investi-
gated in heterologous expression systems6 rather
than by in vivo or ex vivo analysis of patients’
material, because almost all patients with CF are
either homozygous for F508del or compound
heterozygous for two different CFTR mutations.
The investigation of compound heterozygous
individuals does not provide unequivocal informa-
tion about the phenotype of the individual muta-
tion and consequently the in vivo phenotype of a
CFTR mutation can best be studied in homozy-
gotes for a particular CFTR mutation.
This report describes the basic defect of indivi-
duals who are homozygous for non-F508del CFTR
mutations. These rare index cases were identified
during the last 15 years by CFTR mutation analysis
of large patient populations in Germany, Italy and
Israel. A cohort of F508del homozygous sibpairs
from nine European countries7 was used as
reference group. The patients’ defective chloride
transport across the apical membrane of epithelial
cells was measured by the physiological assays
employed when diagnosing CF—that is, the sweat
test,2 the nasal potential difference (NPD)3 and
intestinal current measurements (ICM) of freshly
excised rectal suction biopsies.4 7 CFTR function
was not detectable in individuals who harbour two
CFTR null alleles and close to normal in two
individuals who are homozygous for non-conser-
vative amino acid substitutions.
SUBJECTS AND METHODS
Subjects
The index cases (table 1) selected from CF centres
in Germany, Italy and Israel were investigated at
the CF centres in Verona (patients 3 and 4) or
Hannover (all other patients). Informed consent
was obtained from all patients and at least one
parental guide in case of minors. This study was
approved by the ethics committee of the
Medizinische Hochschule Hannover (study no.
1226). All subjects except patient 2 were offspring
of consanguineous marriages which was documen-
ted by the parental status of first or second
generation cousins in the family tree (patients 1,
3–14) or by the overrepresentation of homozygous
marker genotypes (patients 15–17). Before the date
of the investigation of the basic defect by NPD
and/or ICM, all index cases had been diagnosed
with CF. The diagnosis had been based on clinical
symptoms compatible with CF and/or a positive
family anamnesis, chloride concentrations in the
sweat test .40 mval/l and/or two CFTR sequence
variations not yet described in healthy control
populations. The standardised clinical examination
at the day of assessment8 included family ana-
mnesis, patient’s history, acute clinical symptoms
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and medication, a physical examination, documentation of
meconium ileus, meconium ileus equivalent, hepatobiliary
disease, diabetes mellitus, fertility, other diseases, anthropome-
try, determination of pancreatic elastase in stool as an index for
the exocrine pancreatic status, a lung function test (the forced
vital capacity and the forced expiratory volume in 1 s were
determined by spirometry and expressed as a predictive value
based on Knudson’s formulas9), bacteriology of sputum or deep
throat swab, serum IgG and IgE and antipseudomonal IgG.
After the clinical examination a Gibson–Cooke pilocarpine
iontophoresis sweat test,2 NPD3 and ICM4 measurements were
performed within the next 72 h.
Mutation analysis at the CFTR locus
A cascade approach was taken to identify CFTR mutations in
genomic DNA from nuclear blood cells.10 11 K-EDTA blood
samples were taken from the patient and, at the Hannover site,
also from the parents. First, frequent CFTR mutations were
directly tested by established polymerase chain reaction (PCR)-
based protocols guided by the parental CFTR haplotypes of the
index case. Next, the 27 exons of the CFTR gene together with
their flanking intron regions were amplified separately by PCR.
Before 1995, sequence variations were sought by single strand
conformation polymorphism (SSCP) or restriction enzyme
based analysis of PCR product. All non-F508del mutations
detected by direct testing or anomalous migration behaviour in
SSCP were confirmed by direct genomic sequencing of the
respective exon. Starting by 1995, SSCP was omitted and the
whole coding and flanking intron sequences were determined by
direct genomic sequencing as the second step. Finally, specimens
which were refractory to amplification by PCR were scanned
for genomic rearrangements by Southern hybridisation with
PCR generated genomic probes encompassing the respective
exon and flanking intron sequences. By this cascade approach a
100% detection rate of two CFTR mutations had been achieved
in a cohort of 330 exocrine pancreas insufficient German
patients with CF. Of 52 exocrine pancreas sufficient subjects
with CF, two CFTR mutations were detected in 42 patients and
only one mutation in 10 patients.
Transepithelial NPD measurements3 7
Access to the subcutaneous space was obtained by a needle
filled with NaCl solution inserted subcutaneously into the
forearm. The lower nasal turbinate was superfused with a
polyethylene tube (PE-50) connected via syringes to the various
superfusing solutions. Both the needle and the PE-50 tubing
were connected to a high impedance voltmeter via Ag/AgCl
electrodes and agar/saline-filled salt bridges. The basal PD was
measured by superfusing NaCl buffer A (120 mM NaCl, 25 mM
NaGluconate, 0.4 mM NaH2PO4, 2.4 mM Na2HPO4) over the
nasal mucosa. Subsequently, electrogenic sodium absorption
was blocked with 0.1 mM amiloride in buffer A. To determine
the basal chloride conductance, the nasal mucosa was super-
fused with buffer B (145 mM NaGluconate, 0.4 mM NaH2PO4,
2.4 mM Na2HPO4, 0.1 mM amiloride). Finally the responsive-
ness to 0.1 mM isoproterenol in buffer B, which typically
activates CFTR chloride channels, was tested.
Intestinal current measurements
ICM was performed on freshly obtained rectal suction biopsies
in a micro-Ussing chamber according to our published proto-
col.4 7 The biopsies equilibrated in Meyler’s buffer (gassed with
95% O2–5% CO2)
4 were sequentially exposed to the mucosal
(M) and/or serosal (S) side to: (1) amiloride (1024 M, M); (2)
indomethacin (1025 M, M+S), to reduce basal chloride secretion
by inhibiting the endogenous prostaglandin formation; (3)
carbachol (1024 M, S), to initiate the cholinergic Ca2+-linked
chloride secretion; (4) forskolin (1025 M, M+S) together with 8-
bromo-cAMP (1023 M, M+S), to open cAMP-dependent Cl2
channels like CFTR; (5) 4,49-diisothiocyanatostilbene-2,29-di-
sulfonic acid (DIDS, 2.1024 M, M), to inhibit DIDS-sensitive
Cl2 transporters like the Ca2+-dependent Cl2 channels and the
ORCC; (6) histamine (5.1024 M, S), to reactivate the Ca2+-
dependent chloride secretory pathway.4
RESULTS
Seventeen individuals homozygous for a non-F508del CFTR
mutation were recruited for the study. The patients’ clinical
characteristics and the sweat test, NPD and ICM values are
shown in tables 1–3. The electrophysiological phenotype of the
patients’ basic defect (table 4) was compared with that of
F508del homozygous CF siblings who had been studied
previously by the same protocol and the same core team of
investigators.7 All F508del homozygotes had CF-typical sweat
test, NPD and ICM values (tables 2 and 3).7
Expression of functional CFTR was expected to be absent in
patients harbouring two CFTR null alleles. The homozygotes
for the large out-of-frame 21 kb deletion of exons 2 and 312 of
the CFTR gene (Fig 1B) or the nonsense mutation R553X
showed indeed full-blown CFTR loss-of-function phenotypes in
the bioassays. The two R1162X homozygous patients, however,
had some chloride secretory activity in their intestine that
consisted of both DIDS-sensitive and DIDS-insensitive compo-
nents (fig 1D, tables 4 and 5).
Residual chloride conductance was detected in subjects with
splice site mutations that permit production of some wild type
CFTR. The mutation 3849+10 kb C-T is known to activate a
cryptic splice acceptor site in intron 19 and leads to variable
levels of both aberrant and correct CFTR mRNA transcripts
modulated by splicing factors in a tissue dependent manner.13 14
Accordingly we measured sweat chloride concentrations and
basal NPD values in both the normal and the CF range in two
3849+10 kb C-T homozygous siblings, whereas in contrast only
minute chloride secretion like in most F508del homozygotes
was detected in the ICM. The donor splice mutation 1898+3 A-
G in intron 12 of CFTR15 affects a not obligatorily conserved
position. The homozygous index case presented an electro-
physiological phenotype intermediate between CF and non-CF
(tables 1–3). The DIDS-insensitive chloride secretory responses
to cAMP, carbachol and histamine in the ICM were higher than
those ever seen in patients with an established CF diagnosis, but
were lower than measured before in all non-CF controls (fig 1B).
Consistent with this intermediate phenotype of the basic
defect, the currently 15-year-old patient developed only mini-
mal symptoms of CF respiratory and gastrointestinal disease
and required virtually no treatment.
The in-frame deletion of exon 2 detected by the authors
within the frame of this study showed a variable manifestation
of the basic defect with residual cAMP-activatable DIDS-
sensitive or DIDS-insensitive chloride secretion in two of the
three patients (tables 4 and 5). Absence or presence of residual
chloride secretory activity in the intestine was associated with
severe or very mild courses of clinical CF disease in the three
subjects who received no adequate symptomatic therapy of CF
for prolonged periods of time. The ICM data suggest that the
CFTR mutant lacking exon 2 may confer some residual chloride
secretory activity to the intestine.
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Seven study participants were homozygous for a missense
mutation in the CFTR gene (table 4). By the time of writing,
none of the 5- to 23-year-old individuals had yet experienced
any severe exacerbation of CF pulmonary or gastrointestinal
disease. The homozygotes for E92K,16 W1098L or M1101K17
showed highly elevated sweat chloride concentrations in the CF
range on several occasions, whereas the homozygotes for
G314E18 or L997F19 20 had normal sweat electrolytes like non-
CF healthy controls (table 2). The NPD responses were
heterogeneous in the group. Only the E92K homozygote
showed the CF pattern of a large response to amiloride and of
a low chloride diffusion potential. The missense mutation E92K
results from a G-to-A transition in the first base of exon 4 and
hence may not also lead to the substitution of a glutamate by a
lysine but also may affect splicing as it has been observed for the
stop mutation E92X.21 The G314E and the M1101K homo-
zygotes exhibited an intermediate chloride secretory phenotype
between typical CF and typical non-CF. Rectal epithelial tissue
from all seven subjects exhibited substantial DIDS-insensitive
chloride secretory responses indicating that all analysed CFTR
mutants can transport chloride. The transport rates were in the
upper CF range (E92K, W1098L, one M1101K sibling), in the
intermediate range between CF and non-CF (the other two
M1101K siblings) or in the normal range (L997F, G314E)
(fig 1C). The tissue specimens from two M1101K homozygous
siblings expressed two patterns of chloride secretory responses
that are consistent with the presence of both CFTR and the
alternative chloride channel ORCC (fig 1E, table 5).7 Since the
outcome of NPD, ICM, sweat test and clinical examination was
normal in the G314E or L997F homozygotes, the diagnosis of CF
that had been based on mutation reports in the literature,18 19
positive family anamnesis or suggestive respiratory symptoms,
was withdrawn for these two individuals.
DISCUSSION
This first study of how non-F508del homozygous CFTR
genotypes translate into the basic defect in the major affected
organs in vivo, uncovered the full range from complete loss-of-
function to normal non-CF phenotypes. All patients except
patient 2 descended from consanguineous marriages charac-
terised by an overrepresentation of homozygous genotypes.
Hence we expected the sibpairs in our cohort to be concordant
in their manifestations of aberrant epithelial chloride conduc-
tance, but this was not the case. The siblings showed an
individual rather than a shared electrophysiological signature in
NPD and ICM (tables 2 and 3), suggesting that individual
factors modify the CF phenotype at the level of the basic defect
even though it is more closely related to the mutation genotype
than any clinical symptom.
More than 90% of CF patients are homozygous or compound
heterozygous for F508del,1 and consequently our perception of
CF disease is dominated by this major mutation. Loss-of-
function mutations such as CFTRdele2,3(21 kb) or R553X were
not distinguishable in their clinical phenotypes from those of
F508del homozygotes, although the consequences at the
molecular level such as nonsense mediated decay and exon
skipping22 or defective maturation and trafficking of protein1 are
different.
All other CFTR mutations investigated in this study
translated into facets of disease and basic defect that are
atypical for the most common genotype. Splice site mutations,
for example, were associated with progressive lung disease and a
Table 2 Assessment of basic defect (A): sweat tests and nasal potential difference (NPD) measurements (mV)
Patient number CFTR genotype
Sweat chloride concentration (mval/l)
Basal PD
(mV)
Change in PD (mV)
Day of
assessment
Prior tests
(age) Amiloride
Chloride-free +
isoproterenol
Out-of-frame deletion
1 CFTRdele2,3(21 kb)/CFTRdele2,3(21 kb) 103 95 (10 mo) 260 22 210
Nonsense mutation
2 R553X/R553X 96 100 (16 mo) 262 34 27
3 R1162X/R1162X 98 110 (2 y 1 mo) 248 23 24
4 R1162X/R1162X 104 112 (1 mo) 239 30 0
Splice-site mutation
5 1898+3 A-G/1898+3 A-G 73 69 (4 mo) 233 21 23
6 3849+10 kb C-T/3849+10 kb C-T 92 64 (20 y 5 mo) 244 30 212
49 (28 y 4 mo)
7 3849+10 kb C-T/3849+10 kb C-T 20 50 (11 y 2 mo) 227 12 +3
In-frame deletion
8 CFTRdele2(ins186)/CFTRdele2(ins186) 102 134 (4 mo) 245 30 21
9 CFTRdele2(ins186)/CFTRdele2(ins186) 100 119 (9 y) 248 31 28
10 CFTRdele2(ins186)/CFTRdele2(ins186) 131 100 (4 y) 258 41 212
Missense mutation
11 E92K/E92K 118 93 (8 mo) 252 20 211
12 G314E/G314E 15 43 (6 y 2 mo) 219 4 216
13 L997F/L997F 8
14 W1098L/W1098L 107 118 (2 mo)
15 M1101K/M1101K 108 120 256 33 216
16 M1101K/M1101K 130 120 264 26 215
17 M1101K/M1101K 118 229 13 210
F508del/F508del (n = 74)7 106¡22 256¡10 28¡9 28¡5
non-CF (n = 25) 16¡9 220¡10 11¡6 230¡8
Sibpairs: patients 3 & 4, 6 & 7, 9 & 10, 15, 16 & 17.
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normal sweat test in case of 3849+10 kb C-T13 and with
minimal disease and substantial chloride secretion beyond the
CF range in the ICM in case of 1898+3 A-G.
Missense mutations are a guide to dissect the function of
CFTR motifs and domains. E92K and D110H (data not shown)
are located in the first ectoplasmic loop. The index cases were
prone to severe salt loss upon exposure to heat or exercise, but
otherwise are overweight and have normal lung function.
Hence, the integrity of the loop at these positions seems to be
essential for the reabsorption of salt from the sweat duct, but
less relevant for ion secretion in airways and intestine.
The mutations W1098L and M1101K reside in the cytoplas-
mic loop 4 (residues 1035–1102). Heterologously expressed,
recombinant mutants W1098R and M1101K were defective in
CFTR maturation and non-functional in anion efflux assays.6 In
contrast, the four homozygous patients unequivocally demon-
strated substantial residual chloride conductance in the NPD
and ICM bioassays (table 4). In vitro and in vivo CFTR mutant
phenotypes do not match. Rescue mechanisms are probably
operating in the patients which were absent in the heterologous
host cells in vitro. This example makes the point that in vitro
findings on recombinant mutants should be interpreted with
caution when utilised for counselling of patients and their
relatives.
The non-conservative amino acid substitutions L997F and
G314E did not impair chloride conductance in sweat glands,
airways and intestine. The normal phenotype of the glycine-to-
glutamate substitution is particularly striking. The CFTR
mutation database lists 20 missense mutations with a change
of glycine to an acidic amino acid or vice versa, three of which
are classified as benign sequence variants and eight of which as
disease-causing. Several well characterised severe mutations
occur in the evolutionarily conserved Walker (G1244E, G1249E)
or dodecapeptide motifs (G551D, G1349D) of the ABC
transporter CFTR.1 The missense mutants G622D23 in the
regulatory domain and G314E in the fifth transmembrane
region led to no clinical symptoms of CF. The pathogenetic role
of nine mutations is still unresolved. The same amino acid
substitution thus affects CFTR function to a variable extent
depending on its localisation within the protein. In other words,
the molecular pathology of a missense mutant is hard to predict,
because CFTR topology, function and processing are complex. If
mutation analysis uncovers an uncommon and/or yet unchar-
acterised missense mutation, diagnostic bioassays and in-depth
clinical examination of the index cases need to be pursued in
order to classify the clinical impact of an amino acid
substitution as either neutral, benign or severe.
Our highly selected study cohort of individuals with rare
homozygous CFTR genotypes showed an association with mild
or asymptomatic clinical manifestation if CFTR function was in
the intermediate or normal range in both NPD and ICM. This
positive correlation between the amount of residual CFTR
function and milder disease did not, however, apply to the
individual case, if NPD and/or ICM values were within the CF
range. The two 3849+10 kb C-T homozygotes who started to
develop symptoms of CF respiratory disease during adolescence,
Figure 1 Recordings of short circuit currents. ICM recordings of
individuals homozygous for CFTRdele2,3(21 kb) (A), 1898+3 A-G (B),
G314E (C), R1162X (D), M1101K (E) or of a healthy non-CF individual (F).
The horizontal double-headed arrow corresponds to a recording time of
30 min and each vertical double-headed arrow to a current of 10 mA/
cm2. Please note the twofold contracted scale for tracings C and F. The
arrows indicate the addition of amiloride (1), indomethacin (2), carbachol
(3), cAMP/forskolin (4), DIDS (5) and histamine (6). The tracings show
no (A), intermediate (B) or normal CFTR activity (C, F). The chloride
secretory responses of patients D and E are partially caused by the
expression of alternative chloride channels.
Table 5 Patients’ patterns of residual chloride secretory responses in
intestinal current measurements (ICM)
Chloride
secretory
response
Sensitivity to Interpretation
Patient numbercAMP DIDS Ion channel
Yes Yes No CFTR 3, 4, 5, 6, 7, 10, 11, 12, 13, 14,
15, 16, 17
Yes Yes Yes CACC/ORCC 3, 4, 8, 15, 16, 17
No 1, 2, 9
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and were diagnosed at the oldest age in our cohort, showed the
most severe progression of disease during adulthood leading to
lung transplantation and death; however, patients 1 and 2, with
loss-of-function electrophysiological signature, experienced at
the same age a comparatively high quality of life with no
significant deterioration of their respiratory or gastrointestinal
disease.
In summary, while our study could clearly distinguish
individuals with asymptomatic or atypical CF, no prognostic
value could be derived for the individual case from the amount
of residual CFTR-mediated chloride secretion if the results were
within the CF range. This conclusion should be borne in mind
during genetic counselling of patients or parental guides that
typically takes place early in the life of a CF patient.
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